Open Actively Recruiting

Circulating CD8+ Cell Quantitation as a Predictive Marker of Prolactinoma Response to Dopamine-2 Agonist Therapy

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Eligibility

Minimum Age
N/A
Maximum Age
N/A
Study Stats
Protocol No.
25-2251
Category
Endocrine and Metabolic Disorders
Contact
  • Cristian Santana
Location
  • UCLA Westwood